Salim Mujais is a Nephrology physician affiliated with Sumitomo Dainippon Pharma. OpenAlex indexes 181 publications with 8,060 citations (h-index 44); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2742 The Mews
Northbrook, IL 600622617
Telephone
847-224-5802Registry record last updated 26 Mar 2014.
Clinical trials
- A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
Sponsor: Prolium Bioscience, Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
2 NIH research awards on record, funded 1987–1989 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
Antimicrobial Agents and Chemotherapy
2017 - QT Interval Shortening With Isavuconazole:<i>In Vitro</i>and<i>In Vivo</i>Effects on Cardiac Repolarization
Clinical Pharmacology & Therapeutics
2017 - Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
European Journal of Clinical Pharmacology
2017 - Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
Antimicrobial Agents and Chemotherapy
2016 - Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study
Clinical Pharmacology & Therapeutics
2012
Similar KOLs
Other experts from the same institution or the same specialty.
Andrew Levey, MD
Tufts Medical Center
Glenn M. Chertow
FIND
Bertram Kasiske, MD
Hennepin Healthcare
Garabed Eknoyan, MD
Baylor College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”